CervoMed Inc. (CRVO)

Compare

9.98

+0.83

+(9.07%)

At close: 4:00:02 PM EDT

9.75

-0.23

(-2.30%)

After hours: 4:47:00 PM EDT

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study

GlobeNewswire 7 days ago

CRVO
+9.07%
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how CervoMed Inc. (NASDAQ:CRVO) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever-changing environment. Short squeeze is among the few […]

Insider Monkey 13 days ago

CRVO
+9.07%
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

CervoMed ( NASDAQ:CRVO ) Full Year 2024 Results Key Financial Results Revenue: US$9.74m (up 36% from FY 2023). Net...

Simply Wall St. 14 days ago

CRVO
+9.07%
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where CervoMed Inc. (NASDAQ:CRVO) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting lows, and the energized chase after the next big opportunity – […]

Insider Monkey 14 days ago

CRVO
+9.07%
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary outcome measure- -Plan to initiate Phase 3 trial in mid-2026 following meeting with regulatory authorities- -Awarded 2024 Prix Galien USA Award as “Best Startup” by the Galien Foundation- BOSTON, March 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing tre

GlobeNewswire 15 days ago

CRVO
+9.07%
Why CervoMed Inc. (CRVO) Soared Last Week?

We recently published a list of These 10 Stocks Posted Double-, Triple-Digit Gains Last Week. In this article, we are going to take a look at where CervoMed Inc. (NASDAQ:CRVO) stands against other stocks that posted double-, triple-digit gains last week. Micro- and small-cap companies dominated gains on the stock market last week, bucking an […]

Insider Monkey 15 days ago

CRVO
+9.07%
CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program

JonesResearch upgraded CervoMed (CRVO) to Buy from Hold with a $15 price target arguing that the company’s latest data from the open label extension study is “boosting investor confidence” and the firm sees a “more risk-on approach” heading into the next steps for neflamapimod in dementia with Lewy bodies patients. The firm, which is raising its view of the probability of success in the DLB program to “a highly conservative 10%” while awaiting clarity on the path forward, sees probability-adjust

TipRanks 18 days ago

CRVO
+9.07%
We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 18 days ago

CRVO
+9.07%
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of fall

GlobeNewswire 22 days ago

CRVO
+9.07%
Why CervoMed (CRVO) Is Advancing Today

CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with CRVO’s management and analyzing its recent drug trial results, Boral believes that the company can improve the performance of its neflamapimod […]

Insider Monkey last month

CRVO
+9.07%
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently manufactured batch of neflamapimod — — Pharmacokinetic data obtained in a food-effect study in healthy volunteers in 4Q 2024 indicates that the new capsules achieved targeted mean plasma concentrations — — Within-subject comparison of certain participants who received older capsules during the doubl

GlobeNewswire last month

CRVO
+9.07%
CervoMed to Present at the 8th International Lewy Body Dementia Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on De

GlobeNewswire 2 months ago

CRVO
+9.07%
CervoMed price target lowered to $4 from $45 at Roth MKM

Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported negative top-line results from the Phase 2b RewinD-LB – dementia with Lewy bodies – study of neflamapimod in pure DLB patients, raising questions about the program’s viability, the analyst tells investors in a research note. A potential reason for failure could be the drug’s inability to achieve the desired plasma concentration – a proxy for efficacy – and Cer

TipRanks 3 months ago

CRVO
+9.07%
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees. On December 6, 2024, the Company granted options to purchase an aggregate of 14,753 shares of common stock to two new employees. Each option has an exercise price of $11.91, the closing price of the Co

GlobeNewswire 3 months ago

CRVO
+9.07%
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes, CDR-SB, or any of its key secondary endpoints – change from baseline in Timed Up and Go, TUG, test, change from baseline in a Neuropsychological Test Battery, NTD, and the Clinician’s Glo

TipRanks 3 months ago

CRVO
+9.07%
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

On Tuesday, CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (a measure of dementia severity) or any of its key secondary endpoints – change from baseline in Timed Up and Go (measures a person’s mobility, balance, a

Benzinga 3 months ago

CRVO
+9.07%
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety signal identified— —Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial— —Trial participants continue to receive neflamapimod during open-label extension— BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (“CervoMed” or the “Company”), a clinic

GlobeNewswire 3 months ago

CRVO
+9.07%
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug

There are currently no available treatment options for any form of frontotemporal dementia that have been approved by the EMA or FDA.

Pharmaceutical Technology 4 months ago

CRVO
+9.07%
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB Phase 2b clinical trial in early-stage dementia with Lewy bodies (DLB) in December 2024 BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that its oral investigational d

GlobeNewswire 4 months ago

CRVO
+9.07%
CervoMed Announces Key Senior Leadership Appointments

New hires in key scientific and regulatory roles to advance continued development of neflamapimodBOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medica

GlobeNewswire 4 months ago

CRVO
+9.07%

Performance Overview

Return	CRVO	S&P 500 (^GSPC)
YTD	+326.50%	-4.23%
1-Year	-56.04%	+7.42%
3-Year	-46.77%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CervoMed Inc. (CRVO)

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?

CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

Why CervoMed Inc. (CRVO) Soared Last Week?

CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program

We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Why CervoMed (CRVO) Is Advancing Today

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed price target lowered to $4 from $45 at Roth MKM

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Announces Key Senior Leadership Appointments

Performance Overview